GE HealthCare Technologies Inc. GEHC
- Market cap
- $29.9B
- P/E
- 15.3×
Follow GEHC
GE HealthCare Technologies Inc. (GEHC) Free cash flow
GE HealthCare Technologies Inc.'s free cash flow for fiscal 2025 was $1.5B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $1.6B. Over the past ten years it has ranged from $1.4B (fiscal 2021) to $2.4B (fiscal 2020); the current reading is higher than 29% of that period. Free cash flow has fallen for 3 consecutive fiscal years. GE HealthCare Technologies Inc. ranks 7th of 149 Medical Devices companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.5B | (3.15%) |
| FY2024 | $1.6B | (9.39%) |
| FY2023 | $1.7B | (6.18%) |
| FY2022 | $1.8B | 33.04% |
| FY2021 | $1.4B | (42.15%) |
| FY2020 | $2.4B | 52.34% |
| FY2019 | $1.6B | — |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $68.0M | (39.29%) |
| Mar 2026 | $112.0M | (87.77%) |
| Dec 2025 | $916.0M | 89.65% |
| Sep 2025 | $483.0M | 5,937.50% |
| 18 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BSX Boston Scientific Corporation compare | $3.6B |
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| PHG Koninklijke Philips N.V. compare | $1.8B |
| GEHC GE HealthCare Technologies Inc. | $1.6B |
| EW Edwards Lifesciences Corporation compare | $1.4B |
| DXCM DexCom, Inc. compare | $1.4B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $1.0B |
| STE STERIS plc compare | $936.0M |
| PEN Penumbra, Inc. compare | $215.9M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GEHC
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement